The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Danilova N.V.
Lomonosov Moscow State University
Kalinin D.V.
National Medical Research Center of Surgery named after A.V. Vishnevsky of Ministry of health of the Russian Federation
Oleynikova N.A.
Lomonosov Moscow State University
Chayka A.V.
Herzen Moscow Oncology Research Institute — Branch Campus of the National Medical Radiology Research Center
Khomyakov V.M.
Herzen Moscow Oncology Research Institute — Branch Campus of the National Medical Radiology Research Center
Vychuzhanin D.V.
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Andreeva Yu.Yu.
Russian Medical Academy of Continuous Professional Education
PD-L1 expression in EBV-associated gastric carcinomas
Journal: Russian Journal of Archive of Pathology. 2022;84(4): 5‑12
Views: 3896
Downloaded: 166
To cite this article:
Danilova NV, Sotnikova TN, Kalinin DV, et al. . PD-L1 expression in EBV-associated gastric carcinomas. Russian Journal of Archive of Pathology.
2022;84(4):5‑12. (In Russ.)
https://doi.org/10.17116/patol2022840415
Assessment of the incidence of PD-L1 expression in EBV-associated gastric adenocarcinomas, as well as clarification of the clinical and morphological characteristics and median survival of patients with PD-L1-positive EBV-associated gastric cancer.
Samples of surgical material from 127 patients with stomach cancer were studied. Each sample was stained by in situ hybridization using primers for the Epstein-Barr virus-encoded small RNAs (EBER). Expression of PD-L1 was assessed immunohistochemically (PD-L1 SP263, PD-L1 SP142). The results obtained were compared with the main clinical and morphological characteristics of gastric cancer and median survival of patients.
The detection rate of PD-L1 SP263 and PD-L1 SP142 in EBV-associated gastric adenocarcinoma in our sample was 100% and 76.9% respectively, thus, PD-L1 expression (SP263, SP142) is significantly more frequently detected in EBV-associated gastric carcinomas. It was found that patients with positive expression of PD-L1 in EBV-associated gastric carcinomas are younger (mean age 56.3 years for SP263 and 55.6 years for SP142), belonging to male gender. In addition, this group is dominated by proximal localization of tumors, ulcerative form of growth, tubular histological type, intermediate subtype according to P. Lauren. These characteristics do not depend on the antibody clone: positive expression of SP142 and SP 263 was detected in the same patients with a few exceptions. The overall median survival of patients with positive PD-L1 status SP263 in EBV-associated gastric carcinomas was 35 months, for patients with positive PD-L1 status SP142 — 25 months. Median survival of SP142 PD-L1 positive patients is higher than overall median survival of PD-L1 negative patients in EBV-associated gastric carcinomas. It was found that PD-L1 status in EBV-associated gastric cancer is not a significant prognostic factor
A single PD-L1 status does not significantly affect the prognosis in patients with gastric cancer, including those in the group of EBV-associated carcinomas, and can only be considered in conjunction with ‘classic’ clinical and morphological characteristics, primarily with the stage of the tumor process, since they determine the prognostic properties of the tumor.
Keywords:
Authors:
Danilova N.V.
Lomonosov Moscow State University
Kalinin D.V.
National Medical Research Center of Surgery named after A.V. Vishnevsky of Ministry of health of the Russian Federation
Oleynikova N.A.
Lomonosov Moscow State University
Chayka A.V.
Herzen Moscow Oncology Research Institute — Branch Campus of the National Medical Radiology Research Center
Khomyakov V.M.
Herzen Moscow Oncology Research Institute — Branch Campus of the National Medical Radiology Research Center
Vychuzhanin D.V.
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Andreeva Yu.Yu.
Russian Medical Academy of Continuous Professional Education
Received:
21.03.2022
Accepted:
27.04.2022
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.